Researchers reported in a study published in Circulation: Journal of the American Heart Association.

The journal is usually published on behalf of the societies by John Wiley & Sons, Inc. And is available on the web via Wiley InterScience. Alcoholic liver disease is the second most common indication for liver transplants in the U.S. And Europe. Although reported survival prices after transplantation were identical between alcoholics and non-alcoholics , concerns about alcohol relapse post-transplant have made the practice relatively controversial, especially in light of the shortage of donor organs. To offset this risk, it is common practice to establish a 6 month amount of abstinence from alcohol before listing a patient for liver transplant. Not only may improvement in liver function result, but higher rates of relapse have been reported in individuals who have abstained for under 6 months before going through transplantation.Dosage escalation continues, and stage II studies in chronic, accelerated, and blast crisis CML are being initiated. Regarding to Charles L. Sawyers, M.D., Professor of Medication at the UCLA School of Medicine, and lead author of the scholarly study, The results of the study provide compelling proof supporting the safety and efficacy of treatment with BMS-354825 in patients whose chronic phase CML is usually resistant to standard treatment with imatinib. Additional data and continued individual follow-up, expected to strengthen these results, will available by the right time of the ASH annual meeting. But there is more to be done, both for AYA care and to support survivorship applications that monitor individuals following treatment for childhood cancers.